Meridian Bioscience, Inc. (VIVO)
After hours:
Chart Events
Performance Outlook
| Previous Close | 19.60 |
| Open | 19.61 |
| Bid | 19.53 x 1200 |
| Ask | 19.54 x 1300 |
| Day's Range | 19.28 - 20.13 |
| 52 Week Range | 17.00 - 30.65 |
| Volume | |
| Avg. Volume | 377,042 |
| Market Cap | 847.774M |
| Beta (5Y Monthly) | 0.42 |
| PE Ratio (TTM) | 12.07 |
| EPS (TTM) | 1.62 |
| Earnings Date | Feb 03, 2022 - Feb 07, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | Feb 01, 2019 |
| 1y Target Est | 26.50 |
Fair Value
Related Research
- Meridian Bioscience Inc.VIVO: What does Argus have to say about VIVO?MERIDIAN BIOSCIENCE INC has an Investment Rating of HOLD; a target price of $21.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Medium; and a Value Subrating of Medium.RatingFair ValueEconomic Moat4 days agoArgus Research
- PR Newswire
Meridian Bioscience Announces Retirement of CFO Bryan Baldasare
Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today that Bryan Baldasare, Executive Vice President, Chief Financial Officer, and Secretary, will retire from Meridian effective December 31, 2021. The Company is engaging an executive search firm in the recruitment of a new chief financial officer. The Company appointed Julie Smith to the position of Senior Vice President, Controller, effective December
- PR Newswire
Meridian Bioscience Announces Retirement of Chairman David Phillips
Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today that David Phillips, Chairman of the Board of Directors, will retire from the Board of Directors and not seek re-election when his term ends in January 2022. The Board of Directors will elect a new chair when Mr. Phillips' term expires and will not replace the vacated seat, which will reduce the number of directors to eight.
- PR Newswire
Meridian Launches Two New Air-Dryable™ Mixes for Isothermal Amplification, Powering Shortest Time-to-results in Point-of-care Testing
Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today the launch of its Air-Dryable™ LAMP Mix and Air-Dryable™ RT-LAMP 1-Step Mix. These ground-breaking molecular master mixes are specifically designed for fast isothermal amplification of nucleic acid sequences, not only to facilitate the development of point-of-care ambient temperature-stable assays, but also to accelerate diagnosis.
